Business Context and Reporting Period
This Form 8-K Current Report was filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on December 20, 2022. The registrant is a Delaware corporation focused on life sciences, with principal executive offices in Palo Alto, CA. The report details a material definitive agreement entered into on the filing date regarding a registered direct offering.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $6 million.
- Net Proceeds: Approximately $5.5 million (after deducting placement agent fees and expenses).
- Securities Issued:
- 215,000 shares of Common Stock.
- Pre-funded warrants to purchase up to 1,499,286 shares.
- Common warrants to purchase up to 2,571,429 shares.
- Offering Price: $3.50 per Share and associated Common Warrants; $3.50 per Pre-Funded Warrant and associated Common Warrants.
- Placement Agent Fees: 6.0% of gross proceeds plus expense reimbursement up to $125,000.
Material Changes and Use of Proceeds
The primary material change is the execution of a securities purchase agreement with an institutional investor. The company intends to use the net proceeds for:
- Research and development expenses.
- General corporate purposes.
- Preparation of a marketing authorization application for Dupuytren's contracture in the UK.
- Legal expenses.
Additionally, directors and executive officers entered into 90-day lock-up agreements restricting the sale of their securities.
Guidance, Outlook, and Restrictions
The filing does not provide specific financial guidance or revenue outlook. However, it outlines significant transactional restrictions:
- Issuance Moratorium: The company will not conduct any issuances of Common Stock for 60 days following the closing.
- Variable Rate Transaction Ban: The company will not enter into a variable rate transaction for 12 months following the closing.
- Warrant Terms: Pre-funded warrants are immediately exercisable at $0.0001. Common warrants have an exercise price of $3.50, are exercisable six months after issuance, and expire on the fifth anniversary of the exercisability date.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds received, as the filing states "expected" amounts.
- Confirm the identity of the institutional investor (Purchaser) as it is not named in the summary text.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific redemption rights or anti-dilution provisions.
- Monitor the company's progress on the UK marketing authorization application for Dupuytren's contracture as a key use of funds.
- Check subsequent filings for any breaches of the 60-day issuance moratorium or 12-month variable rate transaction ban.